JP2004515450A5 - - Google Patents

Download PDF

Info

Publication number
JP2004515450A5
JP2004515450A5 JP2001576086A JP2001576086A JP2004515450A5 JP 2004515450 A5 JP2004515450 A5 JP 2004515450A5 JP 2001576086 A JP2001576086 A JP 2001576086A JP 2001576086 A JP2001576086 A JP 2001576086A JP 2004515450 A5 JP2004515450 A5 JP 2004515450A5
Authority
JP
Japan
Prior art keywords
infect
caused
immun
protection against
dis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001576086A
Other languages
English (en)
Other versions
JP2004515450A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/012417 external-priority patent/WO2001078787A2/en
Publication of JP2004515450A publication Critical patent/JP2004515450A/ja
Publication of JP2004515450A5 publication Critical patent/JP2004515450A5/ja
Pending legal-status Critical Current

Links

Description

敗血症に対する保護を提供することに加えて、具現化された複合ワクチンはまた、その他の感染性合併症に対する保護を提供し得る。例えば、このワクチンは、紅斑性狼瘡（エリテマトーデス）を患う患者および鎌型赤血球病を患う患者において生じるＳ．ｅｎｔｅｒｉｔｉｄｕｓによる感染に対する保護を提供し得、そして、それは、この細菌によって引き起こされる胃腸炎および腸熱に対する保護もまた提供し得る。例えば、Ｓ．Ａｂｒａｍｓｏｎら、Ａｒｔｈｒｉｔｉｓ Ｒｈｅｕｍ．、２８、７５（１９８５）；Ｊ．Ｒ．Ｗｒｉｇｈｔら、Ｊ．Ｐｅｄｉａｔｒ．、１３０、３３４（１９９７）；Ｊ．Ｌ．Ｔａｙｌｏｒら、Ｊ．Ｉｎｆｅｃｔ．Ｄｉｓ．、１６７、７８１（１９９３）；ＭＭＷＲ Ｍｏｒｂ．Ｗｅｅｋｌｙ Ｒｅｐ．、４９、７３（２０００）を参照のこと。また、本明細書に開示される方法は、その他の種類のＬＰＳ多糖を含む複合ワクチンを生成することに容易に適用し得、そしてこれらのワクチンは、単独または組み合わせて用いられ、グラム陰性細菌により引き起こされる広範な合併症および感染性疾患に対する予防的保護を提供し得る。これら合併症および感染性疾患としては、Ｓｈｉｇｅｌｌａ、Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ、Ｖｉｂｒｉｏ ｃｈｏｌｅｒａｅ、ＣａｍｐｙｌｏｂａｃｔｅｒおよびＹｅｒｓｉｎｉａの種々の種および／または株によって引き起こされる赤痢および下痢；Ｈａｅｍｏｐｈｉｌｕｓ ｉｎｆｌｕｅｎｚａｅおよびＮｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓによって引き起こされる髄膜炎；腸チフス性または非腸チフス性のＳａｌｍｏｎｅｌｌａによって引き起こされる腸熱；Ｈａｅｍｏｐｈｉｌｕｓ ｉｎｆｌｕｅｎｚａｅおよびＭｏｒａｘｅｌｌａ ｃａｔａｒｒｈａｌｉｓによって引き起こされる中耳炎；Ｐｓｅｕｄｏｍｏｎａｓ、ＭｏｒａｘｅｌｌａおよびＨａｅｍｏｐｈｉｌｕｓの種によって引き起こされる呼吸器感染；Ｃｈｌａｍｙｄｉａ種によって引き起こされるトラコーマおよび性感染病；Ｆｒａｎｃｉｓｃｅｌｌａ ｔｕｌａｒｅｎｓｉｓによって引き起こされるツラレミア；Ｂｒｕｃｅｌｌａによって引き起こされるブルセラ症；およびＹｅｒｓｉｎｉａ ｐｅｓｔｉｓによって引き起こされるペストが挙げられる。例えば、Ｊ．Ｂ．Ｒｏｂｂｉｎｓら、Ｃｌｉｎ．Ｉｎｆｅｃｔ．Ｄｉｓ．１５，３４６−６１（１９９２）；Ｄ．Ｃｏｈｅｎら、Ｌａｎｃｅｔ，３４９，１５５−９（１９９７）；Ｓ．Ａｓｈｋｅｎａｚｉら、Ｊ．Ｉｎｆｅｃｔ．Ｄｉｓ．１７９，１５６５−８（１９９９）；Ｅ．Ｋｏｎａｄｕら、Ｉｎｆｅｃｔ．Ｉｍｍｕｎ．，６２，５０４８−５４（１９９４）；Ｒ．Ｋ．Ｇｕｐｔａら、Ｉｎｆｅｃｔ．Ｉｍｍｕｎ．，６３，２８０５−１０（１９９５）；Ｚ．Ｋｏｓｓａｃｚｋａら、Ｉｎｆｅｃｔ．Ｉｍｍｕｎ．，６８，５０３７−４３（２０００）；Ｈ．Ｊ．Ｊｅｎｎｉｎｇｓら、Ｉｎｆｅｃｔ．Ｉｍｍｕｎ．，４３，４０７−１２（１９８４）；Ｊ．Ｓ．Ｐｌｅｓｔｅｄら、Ｉｎｆｅｃｔ．Ｉｍｍｕｎ．，６７，５４１７−２６（１９９９）；Ｅ．Ｙ．Ｋｏｎａｄｕら、Ｉｎｆｅｃｔ．Ｉｍｍｕｎ．，６８，１５２９−３４（２０００）；Ｊ．Ｓｕｎら、Ｖａｃｃｉｎｅ，１８，１２６４−７２（２０００）；Ｗ Ｈｕ、Ｉｎｆｅｃｔ．Ｉｍｍｕｎ．，６８，４９８０−８５（２０００）；およびＳ．Ｊ．Ｃｒｙｚら、Ｂｃｈｒｉｎｇ．Ｉｎｓｔ．Ｍｉｔｔ．，９８，２４５−９（１９９７）を参照のこと。
JP2001576086A 2000-04-18 2001-04-17 敗血症処置のためのリポ多糖結合体ワクチン Pending JP2004515450A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19773900P 2000-04-18 2000-04-18
US23187500P 2000-09-12 2000-09-12
PCT/US2001/012417 WO2001078787A2 (en) 2000-04-18 2001-04-17 Lipopolysaccharide-conjugate vaccine for sepsis treatment

Publications (2)

Publication Number Publication Date
JP2004515450A JP2004515450A (ja) 2004-05-27
JP2004515450A5 true JP2004515450A5 (ja) 2008-05-22

Family

ID=26893115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001576086A Pending JP2004515450A (ja) 2000-04-18 2001-04-17 敗血症処置のためのリポ多糖結合体ワクチン

Country Status (6)

Country Link
US (1) US7014857B2 (ja)
EP (1) EP1278548A2 (ja)
JP (1) JP2004515450A (ja)
AU (1) AU2001253568A1 (ja)
CA (1) CA2406229C (ja)
WO (1) WO2001078787A2 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
EP1476197B1 (en) * 2002-02-22 2009-01-07 National Research Council Of Canada Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
US20060233776A1 (en) * 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US20050169941A1 (en) * 2004-01-29 2005-08-04 Andrew Lees Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines
EP1996715B1 (en) * 2005-11-23 2012-04-25 National Research Council Of Canada Bacterial antigens and uses thereof
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
US9044517B2 (en) 2009-12-17 2015-06-02 Fina Biosolutions, Llc Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines
WO2013038375A2 (en) * 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
MX365331B (es) * 2013-01-17 2019-05-29 Arsanis Biosciences Gmbh Anticuerpo específico contra e. coli mdr.
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US11446370B2 (en) 2019-03-18 2022-09-20 Janssen Pharmaceuticals, Inc. Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
CA2128212A1 (en) * 1992-01-16 1993-07-22 Shousun C. Szu Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
AU4841693A (en) * 1992-08-31 1994-03-29 North American Vaccine, Inc. Vaccines against group c neisseria meningitidis
US5573916A (en) * 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6645503B1 (en) * 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
EP1476197B1 (en) * 2002-02-22 2009-01-07 National Research Council Of Canada Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue

Similar Documents

Publication Publication Date Title
JP2004515450A5 (ja)
Pier Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen
Murphy Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response
Karalus et al. Moraxella catarrhalis: a review of an important human mucosal pathogen
Podschun et al. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors
Marrie et al. Legionella-like and other amoebal pathogens as agents of community-acquired pneumonia.
Johnson et al. Improved techniques for the preparation of bacterial lipopolysaccharides
Kwon et al. Protection of tilapia (Oreochromis mosambicus) from edwardsiellosis by vaccination with Edwardsiella tarda ghosts
Ahmed et al. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2–5-year-old children
Ruffolo et al. Identification, purification, and characterization of the type 4 fimbriae of Pasteurella multocida
Gu et al. Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis
Holm et al. The Hag protein of Moraxella catarrhalis strain O35E is associated with adherence to human lung and middle ear cells
Ochoa et al. Effect of lactoferrin on enteroaggregative E. coli (EAEC)
Horzempa et al. Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection
WO2002059156A2 (en) Therapeutic compounds structurally-linked to bacterial polypeptides
Bettelheim et al. Serotypes of Escherichia coli that hybridized with DNA probes for genes encoding Shiga-like toxin I, Shiga-like toxin II, and serogroup O157 enterhemorrhagic E. coli fimbriae isolated from adults with diarrhea in Thailand
Horiuchi et al. Type 1 pili enhance the invasion of Salmonella braenderup and Salmonella typhimurium to HeLa cells
WO2007047501A2 (en) Outer membrane vesicles: novel vaccine for gram-negative biothreat agents
Alam et al. Expression of virulence-related properties by, and intestinal adhesiveness of, Vibrio mimicus strains isolated from aquatic environments
AU678549B2 (en) Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
Hunt et al. Clinical and pathological variability of infection by enterohaemorrhagic (Vero cytotoxin producing) Escherichia coli.
Hammerschlag Community-acquired pneumonia due to atypical organisms in adults: diagnosis and treatment
Cross et al. Escherichia coli and Klebsiella vaccines and immunotherapy
Autenrieth et al. Bactericidal properties of Campylobacter jejuni-specific immunoglobulin M antibodies in commercial immunoglobulin preparations
Marinescu et al. Two Cases of Persistent Diarrhoea Associated with Arcobacter sp.